Natural killer cells with a parp inhibitor for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of natural killer (NK) cells—immune cells that fight cancer—and a drug that blocks DNA repair (a PARP inhibitor) to see if it can better control acute myeloid leukemia (AML) that has relapsed or is not responding. The goal is to help your immune system attack the leukemia cells more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acute myeloid leukemia (AML), a blood cancer, but not a specific subtype called promyelocytic leukemia.
- You have already had at least one type of leukemia treatment, such as chemotherapy, a stem cell transplant, or certain targeted drugs.
- Your leukemia has either come back, not fully responded to treatment, or is showing low-level signs of returning (called MRD).
- Your leukemia cells have a specific marker called CD34 (checked on a lab test).
- You are generally able to carry out daily activities (performance status score of 2 or less) and have adequate organ function (kidneys, liver, heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.